APYX Q1 2023: Advanced Energy Guidance Raised as FDA Clearance Unlocks 39% Growth Path

May 11, 2023 | By EarningsIQ Research

APYX’s Q1 results mark a regulatory and commercial inflection, with FDA clearance for Renuvion post-liposuction use driving a guidance raise and renewed U.S. demand. Operational discipline, product innovation, and direct-to-consumer marketing position the business for a return to growth, though international recovery will lag as distributors digest updated FDA communications. Margin structure and sales mix remain in focus as the company navigates the transition from regulatory headwinds to commercial opportunity.

Summary

• FDA Clearance Catalyzes U.S. Reacceleration: Regulatory progress removes key barriers for Renuvion adoption and supports a raised sales outlook.
• Product Launch and Upgrade Cycle Drive Upside: APEX One console upgrades from existing customers exceeded expectations, fueling near-term growth.
• International Rebound Will Be Gradual: OUS (outside U.S.) markets remain cautious, with guidance reflecting delayed distributor response to regulatory updates.

Business Overview

APYX Medical is a medical technology company specializing in advanced energy-based devices for cosmetic surgery and OEM (original equipment manufacturer) components. Its core business centers on Renuvion, a minimally invasive device for soft tissue contraction and body contouring, sold primarily to cosmetic surgeons and aesthetic clinics. Revenue is split between the Advanced Energy segment, which includes Renuvion generators and handpieces, and the OEM segment, which manufactures electrosurgical products for third parties.

Performance Analysis

Q1 revenue modestly declined year-over-year, but exceeded internal expectations due to stronger-than-anticipated advanced energy sales, particularly in the U.S. The business continues to recover from the 2022 FDA safety communication, which had sharply curtailed generator and handpiece sales, especially internationally. U.S. advanced energy sales grew nearly 10% YoY, driven by the launch of the APEX One console and an aggressive upgrade program for existing users, while international generator sales remained depressed—down over 60% YoY—pending distributor confidence in the updated regulatory status.

Gross margin compressed to 62.4%, primarily due to a higher mix of lower-margin OEM sales and product mix shifts within advanced energy. However, operating expenses declined by 6% YoY, reflecting cost discipline and restructuring initiatives. Net loss narrowed significantly, and cash burn improved, aided by working capital efficiency and proceeds from a sale-leaseback transaction. The balance sheet was further strengthened by a new $35 million credit facility and anticipated IRS tax refunds.

• U.S. Generator Upgrades Outperform: Existing customer upgrades to APEX One exceeded forecasts, offsetting slower new customer acquisition.
• OEM Revenue Spike Influences Mix: A 46% YoY OEM revenue increase boosted total sales but diluted gross margin due to lower segment profitability.
• International Sales Drag Persists: Ongoing regulatory overhang outside the U.S. suppressed generator demand, with only modest improvement expected near term.

Overall, Q1 validated APYX’s thesis that regulatory clarity and product innovation can reignite growth, but the recovery will be uneven across geographies and product lines.

Executive Commentary

Strategic Positioning

1. Regulatory Clearance Unlocks Commercial Momentum

The recent FDA 510(k) clearance for Renuvion’s use post-liposuction directly addresses the key safety communication overhang, making APYX the only device cleared for this indication. This regulatory win allows the company to re-engage both lapsed and new customers in the U.S., providing a unique selling proposition and reducing competitive risk for the core advanced energy franchise.

2. Product Innovation and Upgrade Cycle

Launch of the APEX One console, featuring usability and connectivity enhancements, has catalyzed a significant upgrade wave among existing users. The company’s targeted upgrade program, offering discounted trade-ins, has driven immediate revenue upside and improved customer retention, while also laying groundwork for future software-driven value expansion via cloud-enabled features.

3. Direct-to-Consumer Marketing to Drive Utilization

The “This Is Me” campaign marks APYX’s first major investment in patient-driven demand generation, aiming to increase procedure volume and technology adoption. Early feedback from surgeons and patients is positive, with millions of campaign impressions and rising social media engagement, suggesting potential for sustained utilization growth as awareness builds.

4. International Market Caution

OUS distributor activity remains subdued pending further regulatory and market education, with management acknowledging a lag in international generator sales recovery. Guidance assumes only gradual improvement, with upside potential as distributors digest the updated FDA safety communication and local regulatory bodies respond.

5. Capital Structure and Cash Discipline

APYX has taken decisive steps to strengthen liquidity, including a sale-leaseback transaction, new credit facility, and operational cost cuts. These moves provide ample runway to fund growth initiatives and absorb volatility as the business transitions back to a growth footing.

Key Considerations

This quarter marks a strategic reset for APYX, as regulatory clarity and product launches reshape the near-term revenue trajectory.

Key Considerations:

• U.S. Market Reengagement: The combination of regulatory clearance and new product features is expected to drive both reactivation of lapsed users and new account wins.
• Sales Mix Volatility: A higher OEM contribution and evolving product mix will continue to impact gross margin, requiring ongoing attention to pricing and segment profitability.
• International Ramp Uncertain: OUS recovery will depend on distributor confidence and local regulatory alignment, with a lag already factored into guidance.
• Marketing ROI: The effectiveness of the direct-to-consumer campaign will be critical for driving sustained utilization and technology pull-through.
• Balance Sheet Flexibility: Recent capital actions provide a cushion, but cash generation remains a medium-term priority as APYX targets profitability.

Risks

Regulatory risk remains a central concern, particularly for international markets where distributor confidence and local approvals may lag U.S. progress. Gross margin pressure from sales mix volatility and raw material inflation could persist, especially if OEM outperformance continues. Competitive risk is elevated as the company transitions from regulatory overhang to commercial execution, and the effectiveness of direct-to-consumer marketing is unproven at scale. Any delay in cash inflows from tax refunds or slower-than-expected adoption could strain liquidity.

Forward Outlook

For Q2 2023, APYX guided to:

• Total revenue of $14.2 to $15 million, driven by advanced energy sales growth of 53% to 63% YoY
• OEM sales expected to decline approximately 27% YoY

For full-year 2023, management raised guidance:

• Total revenue of $59 to $62 million (33% to 39% YoY growth), with advanced energy sales of $51 to $54 million (39% to 47% YoY growth)

Management highlighted several factors that support the outlook:

• Regulatory tailwinds from four 510(k) clearances and updated FDA safety communication
• Continued momentum from the APEX One console launch and direct-to-consumer marketing

Takeaways

APYX’s Q1 results demonstrate a turning point, with regulatory clearance and new product launches restoring growth visibility in the U.S. and setting the stage for international recovery.

• Regulatory Clarity Drives U.S. Upside: The unique FDA clearance for post-liposuction use has re-engaged both existing and prospective customers, supporting a raised growth outlook.
• Product and Marketing Levers in Play: APEX One upgrades and the “This Is Me” campaign are critical to driving utilization and market share gains, though their full impact will unfold over coming quarters.
• International and Margin Recovery to Watch: Investors should monitor the pace of OUS distributor reengagement and the evolution of sales mix, as these will shape profitability and long-term growth.

Conclusion

APYX enters 2023 with renewed commercial momentum, as regulatory wins and product innovation begin to translate into tangible revenue growth. The company’s ability to convert U.S. opportunity, drive international recovery, and manage margin structure will determine the durability of its turnaround.

Industry Read-Through

APYX’s experience highlights the critical role of regulatory clarity in unlocking demand for energy-based medical devices, particularly in elective procedure markets where physician confidence and patient marketing are tightly linked. Competitors in the aesthetic device sector should expect increased scrutiny of clinical indications and post-market surveillance, as the FDA signals ongoing attention to safety and intended use. The success of direct-to-consumer campaigns as a driver of technology adoption will be closely watched, offering a potential playbook for other device makers seeking to boost utilization and brand equity in a competitive landscape.

APYX Health Care Medical Devices Regulatory Advanced Energy Cosmetic Surgery FDA Product Launch